歌礼制药-B：截至二零二四年十二月三十一日止年度之年度业绩公告及所得款项用途变更

Ascletis Pharma Inc. 1672 (i)ASC30286.3%(ii)ASC30GLP-1R(iii)ASC47β(THRβ)ASC4740 1,980.82,299.4 216.839.5%302.4 144.7300.9 1.SagimetASC40 GLP-1RGLP-1THRββFASNVEGF ASC30 ASC30(BMI)30-40 kg/m2Ib(MAD)(NCT06680440) A S C3028M A D14.3%MAD26.3%MAD14.2%MAD26.2% MAD12ASC30SAE(GI)AE12ASC30MAD1(ALT)(AST)(TBL)ECGsQT(QTc) ASC30 ASC30GLP-1RASC30(NCE) 13IIa ASC30 ASC30Ib ASC30Ib(SAD)(NCT06679959)BMI30-40 kg/m2IbSAD87668ASC3021214 ASC3040NHPs16ASC30 GLP-1ASC30 Ib ASC47 ASC47I bF D AA S C47(semaglutide)IND ASC47LDL-CIb2640 ASC47900.2%291.0%431.7%50ASC47 A S C4790SAEAEAE1 DIOASC472056.7%LDL-CISAD(NCT06427590)ASC4721ASC4790SAEAEAE1AE ASC47THRβASC47 ASC47 ASC22 RSVASC10 HIVASC22 MASHASC40 MASHASC41 ASC41III (rGBM)ASC40 GBMIV1GBM57%2.854.561046.4GBM2GBM56.6%3.21103 ASC61 I ASC40 6.4430%40%5 III 18A.05 1.Louis N, Perry A, Reifenberge RG, von Deimling A, Figarella-Branger D, Cavenee WK,et al. The 2016 World Health Organization classification of tumors of the central nervoussystem: A summary. Acta Neuropathol. 2016;131:803-20.2.20173.Ostrom Q T, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain andOther Central Nervous System Tumors Diagnosed in the United States in 2011-2015[J].Neuro Oncol 2018, 20 (suppl_4): iv1-iv86. DOI: 10.1093/neuonc/noy131.4.Tan J K, Bhate K. A global perspective on the epidemiology of acne [J]. Br J Dermatol 2015,172 Suppl 1(3-12). DOI: 10.1111/bjd.13462.5.Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen ReceptorInhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299.doi: 10.1177/1060028021992055. 17,000 11 1.ASC302.13ASC30IIa3.ASC474.5. Ib 1,980.82,299.4 56.61.3 30.60.5 0.726.0 184.735.1%119.8(i)60.621.1SagimetSagimet(ii)24.5SagimetSagimet24.5 Sagimet 0.4HCV 115.612.0%101.7 (i)(ii)(iii) 216.839.5%302.4 MASH/PBC 0.20.1 2.1453.1%11.8 1 1. 6.14.4 4,3735,667–4044,3736,071 5.40.2® 3090 14.336.2%9.1 4.169.8%1.2 53.5SagimetSagimet 24.87.4 3164931649 31644–531649 34.066.0 40.945.7 15.311.2 56.113.7 () 341.6355.4 978.9866.0 103.598.5 5.262.4%2.0 Viking Therapeutics, Inc.VikingASC41ASC43FITCUSDC ITCITCASC41ASC43F1930337567,0004,038,000VikingITC USDCVikingUSDC 0.60.2 (1)12.916.6(2)12.816.5(3)7.5%6.0% (1)(2)(3)100% 16.612.916.512.8 6.0%7.5% 23122981.3% 136.1144.0 6.46.5 (300,936)(144,715) 5,3578,264 1,966,1622,342,066 12(b)6897311,965,4732,341,335 1,966,1622,342,066 1,966,1622,342,066 1 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, CaymanIslands 2 (a) 2(c) (b) 2 (c) •1•1•16•77 3 (a) (i) 15 68151,048–2,830–2,718 1,28356,596 3 (a) (ii) 1 0 %Sagimet Biosciences Inc.Sagimet53.1%Northridge Health Group (HongKong) Co., LimitedNorthridge46.9% 10%A60.4%B33.7% (iii) 1 5121(a) (b) (c) (i)(ii) 3 (c)(i) iiiSagimet (i) (ii)Sagimet Bioscience Inc.Sagimet 5 (a) iiiiii (i)5(b)(ii)5(b)(iii)1113 (a) PowerTree Investment (BVI) Ltd.P o w e r T r e ePowerTree 16.5%16.5% 21%21%2.5%2.5% 30%30% 25%25% 15%15% 5% 100% 6 (b) (300,936)(144,715) 6(a)6(a) 7 300,936,0001 4 4 , 7 1 5 , 0 0 01 , 0 0 1 , 5 8 8 , 7 0 41,074,103,460 1,042,721,0001,087,134,000(41,132,296)(13,030,540)1,001,588,7041,074,103,460 1525,434–(2)1525,432 3090 152––––5,4321525,432 17,76221,850 10 31649 (i) (ii) 11,227,000 13567,0004,038,000 (iii) 12 (a) (b) 0.0001 (ii) (a) 107,834,00098,531,00078,004,00059,981,00093,780,000 8 6 , 1 9 4 , 0 0 078,961,00044,413,00014,395,00027,010,000 13 Viking Therapeutics, Inc.VikingASC41ASC43FITCUSDC ITCITC(Administrative Law Judge)ASC41ASC43F1930337567,0004,038,000VikingITC USDCVikingUSDC (i)(ii)(iii)(iv) 30.8%82.2%(i) 63.6%(ii)18.6%ASC47 IbLDL-CASC30BMI30-40 kg/m2I bM A DASC30GLP-1R30.8%ASC47ASC30 C1 2C.2.1 78,004,000107,834,1208 0 , 6 4 4 , 0 0 0117,135,59037,970,00036,889,790 41,692,0005,784,210 (www.hkexnews.hk)(www.ascletis.com) 44AE 2 GLP-1RGLP-1 HIV 46INDITCITCLDL-CMASHC3PBCrGBMF. Hoffmann-LaAG RSVSAESagimetSagimet Biosciences Inc.SGMT0.0001THRββUSDCVEGFVikingViking Therapeutics, Inc.%